Target lesion response and outcomes in patients treated with brigatinib vs crizotinib in ALTA-1L
Camidge, D. R. Kim, H. R. Ahn, M. J. Yang, J. C. Han, J. Y. Hochmair, M. J. Lee, K. H. Delmonte, A. Campelo, M. R. G. Kim, D. W.
Camidge, D. R.
Kim, H. R.
Ahn, M. J.
Yang, J. C.
Han, J. Y.
Hochmair, M. J.
Lee, K. H.
Delmonte, A.
Campelo, M. R. G.
Kim, D. W.
Citations
Altmetric:
Abstract
In ALTA (NCT02094573), depth of target lesion response to brigatinib correlated with PFS and OS in patients with crizotinib-refractory advanced ALK+ NSCLC. We evaluated the association between maximum decrease in target lesions and PFS and OS in patients with ALK inhibitor-naive advanced ALK+ NSCLC from ALTA-1L (NCT02737501).
Description
Date
2023
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
Camidge DR, Kim HR, Ahn MJ, Yang JC, Han JY, Hochmair MJ, et al. Target Lesion Response and Outcomes in Patients Treated with Brigatinib vs Crizotinib in ALTA-1L. Journal of Thoracic Oncology. 2023 Mar;18(3):E27-E. PubMed PMID: WOS:000989330100056.